Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Ana Marin Niebla, Eva Gine, Mariana Bastos-Oreiro, Amanda Perez, Alba Cabirta, Fatima De la Cruz Vicente, Marta Canelo Vilaseca, Ana Jiménez Ubieto, Sonia González De Villambrosia, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Pilar Gomez Prieto, Raul Cordoba, Ana Saus Carreres, Alejandro Martin Garcia-Sancho, Ana Maria Garcia-Noblejas Moya, Carlos Grande, Pablo Prieto Martínez, Concepción Nicolás, Antonio Gutierrez, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Maria Teresa Villalobos, Tomas García-Cerecedo, Rosalia Alonso Trillo, Eva Donato, Paola Villafuerte Gutiérrez, Daniel García Belmonte, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Juan-Manuel Sancho, Beatriz De La Cruz, Raja Prince-Eladnani, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2025-3592

Published: 2025

Journal Articles

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez, Ana Saus Carreres, Sonia González De Villambrosia, Marta Canelo, Ana Maria Garcia-Noblejas Moya, Beatriz De La Cruz Benito, Paola Villafuerte Gutiérrez, Fatima De la Cruz Vicente, Juan Carlos Caballero, Ana Jiménez-Ubieto, Daniel García Belmonte, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Alejandro Martin Garcia-Sancho, Carlos Grande, Concepción Nicolás, Antonio Gutierrez, Marina Gomez-Llobell, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Ainara Ferrero Campos, Rosalia Alonso Trillo, Eva Donato, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Pilar Gomez Prieto, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Raul Cordoba, Juan-Manuel Sancho, Eva Gine, Víctor Navarro Garces, Pau Abrisqueta, Ana Marin Niebla

Blood (2025) 146 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2025-3585

Published: 2025

Journal Articles

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

Constantine Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, James Hilger, Remus Vezan, Chan Cheah

Blood (2025) 146 (Supplement 1): 3891.

https://doi.org/10.1182/blood-2025-3891

Published: 2025

Journal Articles

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Philip Thompson, Tamar Tadmor, Hans Herluf Bentzen, Raul Cordoba, Sylvia Snauwaert, Neta Goldschmidt, Martin Simkovic, Jacob Christensen, Javier Lopez Jimenez, Ohad Benjamini, Toshihiko Oki, Andrew J. Steele, Marie Holst Mørch, Ernestine Tucker, Rebecca Valentin, Alexey Danilov, Umberto Vitolo

Blood (2025) 146 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2025-1015

Published: 2025

Journal Articles

Geriatric assessment in hematology (GAH) scale for survival prognostication and early treatment discontinuation in older adults: Final results from the spanish hematogeriatric registry

Isabel González-gascón-y-Marín, Dolly Viviana Fiallo Suarez, Maite Antonio-Rebollo, Ana Isabel Hormigo-Sánchez, Esperanza Lavilla-Rubira, Cristina Barrenetxea Lekue, Raquel Del Campo, Mireia Constans, Teresa Cobo, Marta Cervera, Francisco Taboada-Alameda, Raul Cordoba, Joan Bargay, Santiago Bonanad Boix, Alfonso José Cruz-Jentoft, Monica Ballesteros, Concepción Boqué

Blood (2025) 146 (Supplement 1): 6266.

https://doi.org/10.1182/blood-2025-6266

Published: 2025

Journal Articles

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Raul Cordoba, Maria Carmen Martinez Munoz, Rosa Maria Rodriguez Nunez, Blanca Sánchez-González, Miriam Moreno, Norma Gutiérrez, David Alonso Castronuño, Jimena Cannata, Pilar Gomez Prieto, Laurentino Benito, Tamara Torrado, Joan Buch, Juan Carlos Caballero, Nazaret Dominguez, Raquel Santiago Alonso, Isabel González-gascón-y-Marín, Maria Moya Arnao, Beatriz De La Cruz, Cecilia Carpio, Maria Dolores Gutiérrez-Meca Maestre, Luis Antonio López Gómez, Eukene Gainza, Maria Rocio Figueroa Mora, Paula Fernandez-Caldas, Mariana Bastos-Oreiro, Paola Villafuerte Gutiérrez, Samuel Romero Dominguez, Belen Navarro Matilla, Izaskun Zeberio, Emilia Pardal De La Mano, Antonio Gutierrez, Eva Donato, Javier Nuñez, Teresa Cobo, Begona Mendibil, Inigo Olazabal Eizaguirre, Maria Isabel Gomez Roncero, Cristina Barrenetxea, Haridian de la Nuez, Sara Ferrero, Roberto Trelles, Maria Garcia Roa, Luis Ignacio Sancho Val, Sofia Martin-Consuegra, Maria Luisa Bengochea, Carmen Alonso Prieto, Elena Ramila, Hugo Daniel Luzardo Henríquez, Maria Jesus Peñarrubia, Alfonso Ortiz, Ignacio Mahillo, Eva Domingo Domenech

Blood (2025) 146 (Supplement 1): 6264.

https://doi.org/10.1182/blood-2025-6264

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in routine clinical practice in Spain

Raul Cordoba, María Dolores García, Ruben Fernández, Lucrecia Yanez San Segundo, Raquel Santiago Alonso, Mónica Ballesteros, María José Berruezo, Xabier Gutiérrez, Jose Manuel Puerta, Alicia Rodríguez Fernández, Alexia Suarez Cabrera, Lina María Abenoza, Margarita Fernández, Raul Perez Lopez, Diana Moreno, Jon Badiola, Javier de la Serna

Blood (2025) 146 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2025-2712

Published: 2025

Journal Articles

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

Blood (2025) 146 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2025-3621

Published: 2025

Journal Articles

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Blood (2025) 146 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2025-1875

Published: 2025

Journal Articles

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Joshua Brody, David Belada, Daniel Morillo, Régis Costello, Marek Trneny, Sven de Vos, Gerardo Musuraca, Umberto Vitolo, David Lewis, Jacob Christensen, Marcel Nijland, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Jennifer Marek, Liwei Wang, Malene Risum, Raul Cordoba, Judit Jørgensen

Blood (2025) 146 (Supplement 1): 3736.

https://doi.org/10.1182/blood-2025-3736

Published: 2025

Journal Articles

Effectiveness of comprehensive geriatric assessment (CGA) in older patients with diffuse large B-cell lymphoma (DLBCL) and the impact of frailty in treatment tolerability and survival in a prospective, multicenter study.

Raul Cordoba, Sergio Ramos, Juan Carlos Caballero, Eva Castillo, Ignacio Mahillo, Maria-Angeles Perez, Daniel Morillo, Laura Solán Blanco, Laura Pardo, Ana-Carolina Miranda, Maria-Gabriela Salvatierra, Cristina Gonzalez de Villaumbrosia, Myriam Rodriguez-Couso, Javier Martinez-Peromingo, Ana-Isabel Hormigo

Blood (2025) 146 (Supplement 1): 4508.

https://doi.org/10.1182/blood-2025-4508

Published: 2025

Journal Articles

Geriatric hematologic care in Latin America: Results from a regional survey of hematology centers

Blood (2025) 146 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2025-4417

Published: 2025

Journal Articles

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Marco Ladetto, David Lavie, Tae Min Kim, Eva Gonzalez Barca, Ewa Paszkiewicz-Kozik, Stefan Hohaus, Caterina Patti, Jan Zaucha, Ömür Gökmen Sevindik, Yulia Volchek, Raul Cordoba, Guillermo Rodríguez Garcia, Sebastian Giebel, Benedetta Puccini, Tadeusz Robak, Siruo Wang, Puja Patel, Rushdia Yusuf, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 5516.

https://doi.org/10.1182/blood-2025-5516

Published: 2025

Journal Articles

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Blood (2025) 146 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2025-5510

Published: 2025

Journal Articles

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Daniel Morillo, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Raul Cordoba, Toshihiko Oki, Monica Wielgos-Bonvallet, Mina Khoshdeli, Yi Hao, Jennifer Marek, Malene Risum, David Belada

Blood (2025) 146 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2025-1955

Published: 2025

Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood (2025) 146 (Supplement 1): 63.

https://doi.org/10.1182/blood-2025-63

Published: 2025

Journal Articles

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Joshua D. Brody, Judit Jørgensen, David Belada, Régis Costello, Marek Trněný, Umberto Vitolo, David John Lewis, Yasmin H. Karimi, Anna Sureda, Marc André, Björn E. Wahlin, Pieternella J. Lugtenburg, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Aqeel Abbas, Liwei Wang, Malene Risum, Raul Cordoba

Blood (2025) 145 (15): 1621–1631.

https://doi.org/10.1182/blood.2024026830

Published: 2025

Includes: Supplemental data

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Geriatric assessment in hematology (GAH) scale for survival prognostication and early treatment discontinuation in older adults: Final results from the spanish hematogeriatric registry

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in routine clinical practice in Spain

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Effectiveness of comprehensive geriatric assessment (CGA) in older patients with diffuse large B-cell lymphoma (DLBCL) and the impact of frailty in treatment tolerability and survival in a prospective, multicenter study.

Geriatric hematologic care in Latin America: Results from a regional survey of hematology centers

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only